Full Archive
Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells
Thoracic Cancer 2026 March [Link] Yoshiki Kuwabara, Kosuke Sakai, Kota Shiraishi, Itsuka Matsumoto, Shigeru Ishii, Shin Yokosuka, Masatoshi Abe, Tomoyuki Takahashi, Yuichiro Kawano, Hiroaki Nishimura, Maiko Toda-Sasaki, Yumiko Kobayashi-Ogawa, Satoshi Kikuchi 1, Yusuke Hirata 1, Hiroyuki Kyoyama, Gaku Moriyama, Nobuyuki Koyama, Kazutsugu Uematsu Abstract Background: Pleural mesothelioma is a highly aggressive malignancy with a poor…
Read MoreMedical thoracoscopy with talc poudrage and indwelling pleural catheter insertion versus medical thoracoscopy with talc poudrage alone for patients with symptomatic malignant pleural effusion (TACTIC): a randomised, controlled phase 3 trial
The Lancet. Respiratory Medicine 2026 April [Link] Alexandra Dipper, Anand Sundaralingam, Emma Hedley, Sharada Gudur, Janet Mills, Sandra Sowden, John P Corcoran, Cyrus Daneshvar, Chris Craig, Andrew J Moore, Alice Milne, Amelia Clive, Rahul Bhatnagar, Mark E Roberts, Thapas Nagarajan, Farheen Kutubudin, Helen Wassal, Moustafa Aboushehata, Sana Iftikhar, Mohammed Haris, Manjumol Abraham, Rajini Sudhir, Rakesh…
Read MoreTargeting fatty acid synthase suppresses tumor development in NF2/CDKN2A-deficient pleural mesothelioma
Cell Death & Disease 2026 February 28 [Link] Sivasundaram Karnan, Akinobu Ota, Muhammad Nazmul Hasan, Hideki Murakami, Md Lutfur Rahman, Md Wahiduzzaman, Md Towhid Ahmed Shihan, Nushrat Jahan, Lam Quang Vu, Ichiro Hanamura, Akihito Inoko, Miho Riku, Hideaki Ito, Yoshifumi Kaneko, Yinzhi Lin, Toshinori Hyodo, Hiroyuki Konishi, Shinobu Tsuzuki, Yoshitaka Hosokawa Abstract Pleural mesothelioma (PM)…
Read MoreImmune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: Efficacy, Real-World Outcomes, and the Search for Predictive Biomarkers
Current Oncology 2026 February 3 [Link] Giusi Bondì, Serafina Martella, Dimitrios Stylianakis, Alberto Terminella, Filippo Lococo, Alessia Ciarrocchi, Alfonso Fiorelli, Giacomo Cusumano Abstract Immunotherapy has significantly reshaped the management of malignant pleural mesothelioma (MPM), offering new therapeutic opportunities after decades in which platinum-pemetrexed chemotherapy represented the only systemic option. However, clinical benefit remains markedly heterogeneous,…
Read MoreClinical Importance of Molecular Biomarkers in Pleural Mesothelioma
Cancers 2026 February 19 [Link] Logan Roof, Kenna Koehler, Claire Verschraegen Abstract Pleural mesothelioma (PM) is a rare malignancy with opportunities for improvement in current treatment paradigms despite recent advances in systemic therapy. While histology remains the most clinically relevant prognostic indicator, the expanding use of immunotherapy and ongoing clinical trials involving targeted therapies have…
Read MoreFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Journal of Clinical Oncology 2026 March 20 [Link] Arnaud Scherpereel, Paul Baas, Anna K Nowak, Anne S Tsao, Nobukazu Fujimoto, Solange Peters, Aaron S Mansfield, Sanjay Popat, Yolanda Bautista Aragon, Toby Talbot, Francesco Grossi, Dariusz Kowalski, Muhammet A Kaplan, Andrés Felipe Cardona, Raheela Soomro, Nan Hu, Adam Lee, Virginia Ip, Yu-Han Hung, Gérard Zalcman Abstract…
Read MoreMesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models
Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma de Jong, Joel Kidman, Rachael M Zemek, Catherine A Rinaldi 6, Timo Lassmann 3, Anthony Bosco 7, Y C Gary Lee, Richard A Lake, Jonathan…
Read MoreMesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models
Scientific Reports 2026 February 25 [Link] M Lizeth Orozco Morales, Sally M Lansley, Wee Loong Chin, Caitlin M Tilsed, Nicola Principe, Connull Leslie, Breana J Vitali, Francois X Rwandamuriye, Emma de Jong, Joel Kidman, Rachael M Zemek, Catherine A Rinaldi, Timo Lassmann, Anthony Bosco, Y C Gary Lee, Richard A Lake, Jonathan Chee, W Joost…
Read MoreStrategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype
PLoS One 2026 February 23 [Link] Xuerao Ning, Thảo Thi Thanh Nguyễn, Takao Morinaga, Yuji Tada, Hideaki Shimada, Kenzo Hiroshima, Naoto Yamaguchi, Masatoshi Tagawa Abstract Mesothelioma has characteristic genetic changes including inactivation of neurofibromatosis type 2 (NF2) and deletion of the INK4A/ARF region. Cells deficient of NF2 protein (MERLIN) depend on focal adhesion kinase (FAK)…
Read MoreMoving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma
Journal of Thoracic Oncology 2026 February 20 [Link] Gabrielle Drevet, Lipika Kalson, Laurane Mangé, Francoise Galateau-Salle, Arnaud Scherpereel, Lara Chalabreysse, Julien Mazières, Luka Brcic, Nicolas Alcala, Jean-Michel Maury, Lynnette Fernandez-Cuesta, Matthieu Foll Abstract Despite recent advances in the treatment of pleural mesothelioma, it remains a challenging and heterogeneous disease, with limited options for patients. Survival…
Read More
Skip to content